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Background: Recent observations suggest that immune-mediated tissue destruction is dependent upon
coordinate activation of immune genes expressed by cells of the innate and adaptive immune systems.
Methods: Here, we performed a retrospective pilot study to investigate whether the coordinate expression of
molecular signature mostly associated with NK cells could be used to segregate breast cancer patients into relapse
and relapse-free outcomes.
Results: By analyzing primary breast cancer specimens derived from patients who experienced either 58–
116 months (~5-9 years) relapse-free survival or developed tumor relapse within 9–76 months (~1-6 years) we
found that the expression of molecules involved in activating signaling of NK cells and in NK cells: target interaction
is increased in patients with favorable prognosis.
Conclusions: The parameters identified in this study, together with the prognostic signature previously reported by
our group, highlight the cooperation between the innate and adaptive immune components within the tumor
microenvironment.
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Increasing evidence indicates that some patients with
cancer can generate an adaptive immune response spe-
cifically directed against antigenic proteins expressed by
tumors. In particular, an adaptive T cell response, which
is composed of both cytotoxic CD8+ T cells (CTLs) and
CD4+ T cells, can promote the secretion of cytokines
such as interferon gamma (IFNγ) and tumor necrosis
factor alpha (TNFα) generating an acute inflammation
which results in expansion of cytotoxic CD8+ T cells,
tissue destruction and control of cancer growth [1].* Correspondence: asciertoml@cc.nih.gov
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reproduction in any medium, provided the orAccordingly, an “adaptive immune response” signature
has been associated with improved outcomes in several
tumour types [1-4]. Thus, in the context of tumor
immune surveillance most emphasis has been placed on
adaptive immune responses while the role of innate
immune cells and their cross talk with adaptive immune
cells as played a minor role. However, recent observa-
tions suggest that immune-mediated tissue destruction,
which includes tumour regression, is dependent upon co-
ordinate activation of immune effector genes expressed by
cells of the innate and adaptive immune systems [1,5-8].
Recently, we have shown that the anti-tumour efficacy of
Adoptive Cell Therapy (ACT) in the FVBN202 transgenic
mouse model of breast carcinoma depended on the pres-
ence of tumour-specific T cells as well as activated Natural
Killer (NK) cells and NKT cells [9]. Among cells of the
innate immune system, the NK cells represent a subset ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumour cells and participate in antitumor responses [10].
The effective function of NK cells is strictly dependent on
the balance in the expression of activating and inhibitory
receptors which are able to interact with ligands present
on the target cells [11]. NK cells also express adhesion
molecules able to interact with tumour cells or dendritic
cells (DCs), resulting in NK cell cytotoxicity or enhanced
DC activation, respectively. The anti-tumour effect of NK
cells has been well documented especially in animal
models showing that reduced NK cell activity leads to a
high incidence of tumour occurrence and metastasis
[12,13]. Tumour rejection in mice has been correlated
with precursor frequency of both tumour-specific CD8+ T
cells and NK effector cells that interact with tumour cells
via activating receptor Natural Killer Group 2D (NKG2D)-
mediated mechanisms [14]. In humans, while prognostic
T cell signatures are widely established, the role of NK
cells or other immune effector cells has been poorly
appreciated. Only recently it has been observed that a
decrease in the expression of the activating receptors
NKG2D and DNAX accessory molecule 1(DNAM1) by
NK cells is associated with tumour progression in breast
cancer patients [15]. Similar observations were made in
the tumour types such as chronic lymphocytic leukaemia
(CLL) and gastrointestinal stromal tumours (GIST)
[16,17], showing that an increased expression of Natural
Cytotoxicity Receptors (NCRs) was associated with sur-
vival of patients. Recently, we reported that an increased
expression of the immune function genes was associated
with relapse-free survival in patients with breast cancer
[18]. Using the same cohort of patients, we sought to de-
termine prognostic value of the innate immune response
characterized by a differential expression of molecular sig-
natures mostly associated with activating signalling of NK
cells and their crosstalk with target cells. Here, we showed
that the expression of Natural Cytoxicity Receptor 1
(NCR1), considered the most accurate surface markers for
human NK cell identification [19,20], together with mole-
cules mostly associated with NK cells and involved in
NK cells: target cells interactions, are associated with
prolonged relapse-free survival in breast cancer patients.
On the contrary, we found that differential expression of
CD56 and CD16 in tumour specimens as well as the
expression of Killer-cell Immunoglobulin-like Receptors
(KIRs) transcripts failed to do so.
Material and methods
Clinical specimens
Patients experiencing either 58–116 months (~5-9 years)
relapse-free survival or tumour relapse within 9–76 months
(~1-6 years) following initial surgery were studied. Samples
were collected from female breast cancer patients’ definitive
surgery specimens. Specimens with unknown tumour stage,lost to follow-up or HER-2/neu borderline were not in-
cluded in our analyses. Frozen tissues derived from 14 pa-
tients (7 who were relapse-free and 7 whose tumours
relapsed) were used for microarray analysis. Among the
samples screened by microarray, only 11 samples were also
screened for RT-PCR because of lack of additional total
RNA to analyse. Additionally 5 new samples were included
in the RT-PCR analysis reaching a total group of 16 ana-
lyzed samples. Paraffin-embedded tissues derived from 9
patients including 4 relapse patients and 5 relapse-free
patients were also used for immunohistochemistry (IHC).
Patients used in each assay and detailed patients’ information
are further described in Additional file 1: Table S1.
All the patients have signed an Informed Consent
Form and approved the publication of this report and
any accompanying images. The study was reviewed and
approved by the Institutional Review Board (HM10920
and 2471-Tissue Acquisition System for Cancer Research) at
Virginia Commonwealth University.
RNA amplification, probe preparation, microarray
hybridization
Gene profiling analysis was performed on a 36 k human
oligo array as previous described [21].
Whole-genome human 36 K oligo arrays, representing
25100 unique genes of the Operon Human Genome
Array–Ready OligoSet version 4.0 were printed in house
using oligos purchased from Operon. The designed is
based on Ensemble Huma Databasebuil NCBI-35c, with
a full coverage on the NCBI human Refseq dataset
(04/04/2005).
Reference for human arrays was obtained by pooling
PBMCs from 6 normal donors.
Total RNA from tumour and reference samples were
isolated and amplified into antisense RNA (aRNA) as
previously described [22,23]. Both reference and test
aRNA were directly labelled using ULS aRNA Fluores-
cent Labelling kit (Kreatech Diagnostics, Amsterdam,
The Netherlands) with Hy3 and Hy5 respectively and
co-hybridized to the slides. After 20 hours of incubation
at 42°C, the arrays were washed, dried and scanned
using the Agilent Microarray Scanner.
Real-Time (RT)-PCR
Real Time-PCR was assayed by TaqMan® Gene Expres-
sion Assays (Applied Biosystems, Foster City, CA) using
an ABI PRISM 7900HT Sequence Detection System.
Primers and probes were obtained from ABI (TaqMan
Assays-on-Demand gene expression products, Applied
Biosystems). To normalize the amount of source RNA,
18S transcript from the same sample was measured and
used as internal reference. Each targeted transcript was
validated using the comparative Ct method for relative
quantification (ΔΔCt) reference to the amount of a
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healthy donors. The fold difference between relapse-free
and progressing groups was calculated using the com-
parative 2–ΔΔCt [24].
Statistical analysis
Microarray data were uploaded to the mAdb databank
(http://nciarray.nci.nih.gov) and further analysed using
Partek (St. Louis, Missouri, USA) and BRBArrayTools
developed by the Biometric Research Branch, NCI (http://
linus.nci.nih.gov/BRB-ArrayTools.html) [25]. The whole
gene expression profile consisted of 25100 genes. Un-
supervised analysis was performed for class confirmation
using Stanford Cluster Program and TreeView software
[26]. Gene ratios were average corrected across experi-
mental samples and displayed according to uncentered
algorithm. Functional gene network analysis was performed
using the Ingenuity Pathway Analysis system (IPA).
RT-PCR data were analysed using MedCalc Software
(Mariakerke, Belgium), StatGraphics Centurion (Warrenton,
Virginia, USA) and BRBArrayTools; to determine the dif-
ference of mRNA expression among relapse and relapse-
free groups Mann-Witney test using MedCalc Software
and StatGraphics Centurion were considered. Survival
analysis, survival risk prediction analysis and Support Vec-
tor Machine (SVM) were performed using BRBArrayTools
[25]. Univariant Cox proportional hazards models were fit
to test individual NK selected gene expression levels for
association with survival (Wald test, two-sided). Kaplan-
Meier survival curves were plotted for patients with ex-
pression levels above and below the median for each NK
selected gene. Permutation p-values for significant genes
were computed based on 10000 random permutations.
Hazard ratio is considered as the ratio of hazards for a
two-fold change in the gene expression level. It is equal to
exp(b) where b is the Cox regression coefficient.
A survival risk prediction model was built using the
supervised principal component method of Bair and
Tibshirani [27]. A Cox proportional hazards model was
fit to relate relapse time to the first two principal com-
ponent linear combinations of expression levels from 8
significantly expressed genes screened by RT-PCR. In
order to evaluate the predictive value of the method,
leave-one-out cross-validation was used. A high relapse
index value corresponded to a high predicted hazard of
relapse with correspondingly poor predicted outcome.
The cross validated Kaplan-Meier survival curves were
plotted for cases predicted to have above average risk
(relapse index above the median in the cross-validated
model) and for cases predicted to have below average
risk (relapse index below the median in the cross-
validated model). A permutation analysis was performed
in which the relapse data was randomly shuffled among
cases 1000 times and the entire cross-validation processwas repeated in order to assess whether the association
of expression data to relapse data was statistically signifi-
cant. The log-rank statistics was generated for those
permutations.
Support vector machine (SVM) with linear kernel
functions was used to develop the prediction model for
distinguishing relapse-free patients and progressing
patients.
In order to estimate how accurately the classes can be
predicted by this multivariate class predictor, the leave-
one-out cross-validated (LOOCV) misclassification rate
as well as cross- validation ROC curve analysis were
computed. Permutation p value for the cross-validated
misclassification error rate was also calculated by ran-
domly shuffling the class labels 1000 times and repeating
the entire cross validation procedure.
Gene expression-based Outcome for Breast cancer
Online (GOBO) tool (http://co.bmc.lu.se/gobo) [28], was
used to perform in silico analyses and develop Kaplan-
Meier analysis on for breast cancer patients (n = 115)
derived from four publicly available breast cancer
datasets of gene expression [29-32]. The results were
stratified into the two quintiles based on gene expression
level of NCR3(NKp30), NCR1(NKp46), CD96, CRTAM,
DNAM1 and NKG2D.
Immunohistochemistry (IHC)
Slides from paraffin-embedded tumour specimens were
subjected to Dako automated immunostainer (Dako,
Carpinteria, CA). Anti-human antibodies towards NCR1
(NKp46) (Abcam Ab14823, 1:100), LFA-1 (Abcam
ab52895, 1:250) and CD1d (Abcam, Ab11076, 1:100) were
used. The antigen retrieval was achieved using DAKO PT
module at high PH. In order to circumvent the endogen-
ous biotin activity, we used Dako Envision Dual Link
System-HRP (Dako, Capinteria CA) in a two-step IHC
technique, based on HRP labelled polymer which is conju-
gated with secondary antibodies. The labelled polymer
does not contain avidin or biotin, thereby avoiding the
nonspecific endogenous avidin-biotin activity in the
sections.
Results
Differential expression of genes involved in NK signature
in breast cancer patients with favourable prognosis
Microarray analyses were performed on amplified RNA
extracted from frozen tissues derived from 14 patients
with either relapse free survival or tumour relapse
(Additional file 1: Table S1). Unsupervised clustering
performed on the filtered gene set (see material and
methods) and based on DNAM1, NCR3(NKp30), CD96
and Class I–Restricted T-cell–Associated Molecule
(CRTAM) expression signatures was able to spontan-
eously segregate the breast cancer patients in two
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(p ≤ 0.001) was used to identify genes differentially
expressed in relapse-free and relapsed groups. The cohort
of the identified genes was further analyzed by IPA show-
ing that genes involved in NK-DCs crosstalk (Additional
file 2: Figure S1) and NK cells signalling (Additional file 3:
Figure S2) were over-expressed in patients with favourable
prognosis.
Expression of genes involved in NK signature correlates
with previously identified immune function gene
signatures associated with favourable outcome
To test whether the expression of molecules mostly asso-
ciated with NK cell signature correlated with the expres-
sion of 5 gene prognostic signature (STAT1, GBP1,
OCLN, IGKC and IGL@) previously described by our
group [6], a similarity matrix based on Pearson correlation
was assembled considering 15 genes (KIR3DL3, KIR2DL3,
KIR3DL2, KIR2DL4, CD84, NCR3(NKp30), CD96,
CRTAM, DNAM1, CD1d, IGK@, GBP1, STAT1, IGLL5,
and OCLN). We observed that the expression of genes
involved in NK crosstalk with DCs and tumour cells



















Figure 1 Expression of genes involved in prognostic NK signature. A)
and interaction with tumour cells. B) Similarity matrix based on Pearson co
NKT and genes previously identified to predict breast cancer patients’ clinic
C) Principal Component Analysis based on 15 genes evaluated in 1B comp(NCR3(NKp30)) or modulating NKT activity (CD1d) was
strongly and positively correlated with that of the 5 previ-
ously identified markers of good prognosis. Conversely,
genes known to encode for surface proteins that mediate
MHC class-I mediated inhibition of NK cells, such as the
KIRs receptors showed a negative correlation with the
identified 5 immune gene signature (Figure 1B). Interest-
ingly, there was an inverse correlation between the expres-
sion of the activating NK receptors, DNAM1 and NCR3,
and CD84, a member of the signaling lymphocyte activa-
tion molecule (SLAM) immunoglobulin super family.
Interaction of CD84 with SH2D1 provides activating stim-
uli for NK cells and T cells. On the other hand, the expres-
sion of CD84 has been reported to be critical for the
survival of Chronic Lymphocytic Leukemia (CLL) [33]
cells, suggesting an involvement in malignancy. Such
controversial reports suggest that the biologic function of
CD84 still remains to be determined.
Principal Component Analysis (PCA) based on the 15
genes set demonstrated that relapse-free patients (red
colour) segregated apart from those with tumour relapse
(Figure 1C), suggesting that the selected signature could
be used to clearly differentiate the two cohort of patients.


















































































-`1                                       +1
Unsupervised clustering based on genes involved in NK cell activation
rrelation assayed on a total of 15 including genes associated with NK,
al outcome genes [6]. Genes previously identified are indicated with *.
aring relapse-free (red colour) and progressing (blue colour) patients.
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cells are finely regulated at the transcriptional level and
activating pathways are important modulators of NK func-
tion in the tumour microenvironment.
Increased expression of NK activating genes and NK
adhesion molecules in patients without recurrence
Results obtained from microarray analysis were further
validated by conducting RT-PCR analysis. Because of the
lack of additional total RNA, only 11 out of 14 samples
previously screened by microarray analysis, were used
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Figure 2 RT-PCR analysis of relapse free and progressing patients. A)
encoding for molecules involved in NK crosstalk with target cells; C) Expres
different isoforms of NCR3 (NKp30).independent samples, not previously screened by micro-
array analysis, were included in the analysis. Total RNA
derived from the specimens of the16 patients were eval-
uated for the expression of 4 adhesion molecules which
although not only expressed by NK cells are mostly in-
volved in NK-target cells interaction (CRTAM, CD96,
CD1d and Leukocyte Function-associated Antigen
1-LFA-1). Also genes involved in NK cell identification
and activation were investigated (CD56, CD16, NKG2D,
DNAM1). As already mentioned the above molecules
are mostly associated with NK cells identification, activa-
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Expression of NK identification markers ; B) Expression of genes
sion of genes involved in activation of NK functions; D) Expression of
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Therefore 3 additional genes (NCR1(NKp46), NCR2
(NKp44), NCR3(NKp30)) mostly restricted to NK cells
[19] were screened. Intrigued by the fact that the expres-
sion of the 3 different isoforms of NCR3(NKp30) was
differently associated with prolonged survival of patients
with gastric GISTs [16], we performed quantitative RT-
PCR using NCR3(NKp30) primers specific for the three
isoforms, in order to investigate whether the expression of
different isoforms of NCR3(NKp30) was differentially asso-
ciated with the clinical outcomes also of individuals with
breast cancer. Furthermore, we studied the expression of
Forkhead box P3 (FOXP3), usually associated with the pres-
ence of T regulatory cells (Tregs) known to inhibit the
activity of NK cells and to promote immune suppression
function [34]. Based on differential expression of CD56 and
CD16, NK cells did not vary between relapse free and
progressing groups (p value = 0.3 and 0.8, respectively)
(Figure 2A). However, tumours from patients with no
recurrence were characterized by increased expression of
genes involved in the interaction between NK cells and
dendritic cells or tumour cells such as CD1d, CRTAM and
CD96 (Figure 2B) and genes involved in activating signal-
ling of NK cells such as NCR1(NKp46), DNAM1 and
NKG2D (Figure 2C). Although all the three isoforms of the
activating receptor NCR3(NKp30) are showed to be over
expressed in the relapse-free group, only isoform1 was
found to be significantly different (Figure 2D). Although
not statistically significant, the activating receptor NCR2
(NKp44) and the adhesive molecule LFA-1 were increased
in the relapse free group (Figure 2B-2C).
Interestingly, RT-PCR results also highlighted a positive
correlation between the expression of FOXP3 and
favourable prognostic NK cells signature (Additional file 4:
Figure S3A). One of the limitations of the current analysis
is that the RT-PCR screening was mostly conducted on
specimens already screened by microarray analysis and
only 5 independent specimens were used. Thus, we can-
not conclude that the differences observed are not biased
by the individual genetic characteristics of the tumours; in
order to widely validate the obtained results additional
breast specimen’s collection is currently ongoing.
Lack of prediction of breast cancer patients based on KIRs
expression
Together with the 12 genes mentioned above, all 16
patients were also screened by RT-PCR for the expression
of KIR2DL3, KIR3DL3 and KIR2DL2. The obtained data
showed that expression of KIRs was not significantly
different in groups with differential survival outcome
(Additional file 4: Figure S3B) suggesting that genes in-
volved in activating rather than inhibitory function of NK
cells should be considered a potential predictive signature
for better survival in breast cancer patients.Increased percentage of CD1d + and LFA + tumour cells in
patients without recurrence
Protein validation analysis was performed by IHC using a
set of 9 validation samples (Additional file 1: Table S1).
Low levels of protein expression didn’t allow a clear detec-
tion of the NK specific marker NCR1 (NKp46) in both
relapse-free and progressing patients (data not shown).
Instead, tumour specimens of patients with relapse-free
survival showed a higher percentage of CD1d + cells.
Moreover a higher percentage of LFA-1+ cells was ob-
served in patients with better outcome (Additional file 4:
Figure S3C). The presence of CD1d and LFA on NKT cells
and a small population of CD8+ cells, together with the
lack of detection of Nkp46 signalling, didn't highlight a
specific involvement of NK cells in favourable prognosis,
at protein level. Although we consider this as a limit of
our study, since we are looking for molecular signatures
that may be associated with the potential triggering rather
than with identification of individual cells involved with
favourable outcome, the absence of additional IHC infor-
mation can be considered a minor obstacle. In addition, if
we consider that the screening of NK cells by IHC has
always been centre of debate for lack of specificity and/or
lack of protein detection, a molecular screening might
seem more appropriate.
NK cell signature predict patients outcome based on
support vector machine prediction model
To test whether the genes screened by RT-PCR could be
used to predict breast cancer patients’ outcome, SVM was
used to develop the prediction model for distinguishing
relapse-free patients and progressing patients. Among all
the genes screened by RT-PCR, only 8 genes (DNAM1,
CD96, CD1d, NKG2D, FOXP3 and NCR1(NKP46), NCR3
(NKP30) isoform1 and CRTAM) with significantly differ-
ence p ≤ 0.05 between the two cohorts of patients were
used in the following analysis.
LOOCV analysis showed that the combination of the
selected genes was able to predict with an accuracy of
81% patients’ outcome with 90% sensitivity and 66%
specificity (Table 1). Based on 1000 permutations, the
support vector machines classifier had p-value of 0.004
confirming that among the screened markers, the genes
involved in NK cells function are significant predictors
of breast cancer outcome. The same results were con-
firmed by Cross- Validation ROC curve analysis re-
sulting in Area Under the Curve (AUC) equal to 0.91
(Figure 3A).
Survival analysis and survival risk prediction model based
on NK cell signature
In order to evaluate whether the molecular expression of
genes differentially expressed among progressing vs.
relapse-free groups could predict the survival of breast
Table 1 Performance of the support vector machine
classifier
Class Sensitivity Specificity PPV NPV
0 0.9 0.667 0.818 0.8
1 0.667 0.9 0.8 0.818
Support vector machine predictor was built as a linear function of the
log-ratios of the expressions of 8 genes screened by RT-PCR. According to our
LOOCV results, the 8 selected genes were able to predict with an accuracy of
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Figure 3 Prediction models associated with survival and clinical outco
based on 8 genes (NCR1(NKP46), NCR3(NKp30) isoform1, NKG2D, CRTAM, D
free and progressing patients based on RT-PCR analysis; B) Survival analysis
Kaplan Mayer curves of 4 genes with significant p value; C) Survival risk pre
analysis, using RFS as endpoint, for breast tumors (n = 115) stratified into th
(NKp30), NKG2D, DNAM1 and CD96.
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analysis based on Cox proportional hazard models. Among
the 12 genes screened by RT-PCR, only the 8 genes with
significant differences among the two cohorts of patients
were used in the following analysis.
Survival was related to each gene testing the hypothesis
that survival time is independent of the expression level for
that gene. A gene list was created based on the resulting p
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eries. The results showed that the expression of CD96,
NKG2D, CD96 and NCR1(NKp46) were significantly asso-
ciated with survival of breast cancer patients (Figure 3B-
Additional file 5: Table S2). Furthermore, survival risk
prediction analysis demonstrated that the combined expres-
sions of the selected genes was associated with decreased
risk of disease progression, although the limited number of
patients used in the analysis didn’t allow the permutation
p-value of the log-rank test statistics between risk groups to
be significant (p = 0.1, Figure 3C). In order to test whether
the described result was associated with the age of patients
or with their status of Estrogen Receptor (ER), Progesterone
Receptor (PR), and Human Epidermal Growth Factor
Receptor 2 (HER2) status rather than being related to the
expression of NK cell signature described above, we
performed a survival risk analysis using age, ER, PR and
HER2 status as covariants. The results didn’t show an asso-
ciation between decreased risk of disease progression linked
with the ER, PR and HER2 expression nor with age
(Additional file 4: Figure S3D). In order to determine
whether small number of samples may affect our results, by
using GOBO tool [28] we conducted survival analysis on a
larger cohort of breast cancer patients (n = 115) derived
from four publicly available breast cancer datasets of gene
expression [29-32]. Kaplan Meyer curves showed a signifi-
cantly (p < 0.03) better survival for patients that showed
higher expression of the NCR3 (NKp30), NCR1(NKp46),
CD96, CRTAM, DNAM1 and NKG2D (Figure 3D).
Discussion
The relevance of anti-tumour immune responses as mod-
ulators of cancer growth is increasingly recognized and
most emphasis has been placed on adaptive immune
responses. Yet, cross talk between the innate and adaptive
immune systems may be a prerequisite for tumour rejec-
tion as recently described [1,8,35-37]. NK cells are pro-
posed to be one of the major cells of the innate immune
system involved in anti-tumour protection [37]. In human,
it has been shown that the presence of intratumoral NK
cells is positively correlated with favorable prognosis in
colorectal, renal, lung cancer and hepatocellular carcin-
oma [38-41]suggesting that NK cells may represent a po-
tential prognostic marker [42]. However, in the majority of
these studies NK cells have been detected according to the
expression of CD57 or CD56 markers which inaccurately
identify NK cells since they are also expressed by other
tumor-infiltrating lymphoid cells. Thus the involvement of
NK cells in tumor immune surveillance has always been
in the centre of debate.
Recently the advent of high throughput technology,
mostly based on gene expression profiling has shown
the relevance of the prognostic infiltration of NK cell
markers at the tumor site.A recent meta analysis conducted on a large publicly
available set of microarray data from primary breast
tumours suggested that breast cancer displayed variable
expression of ligands for NK cell receptors. In particular,
NKG2D-ligands and DNAM1-ligands, known for their
NK cell activating function, were found to be widely
expressed across all breast cancer subtypes [43]. The
same group reported that expression of activating NK
cell receptors decreased while expression of NK cell
inhibitory receptors increased during breast cancer
progression [15]. However, a comparative analysis of the
expression of these markers in primary tumours directly
linked to relapse-free survival has not been performed.
In the present study, we used gene expression profil-
ing, RT-PCR and IHC analysis to detect the expression
of activating and adhesive NK cell receptors in primary
breast cancer specimens derived from patients who
experienced either 58–116 months (~5-9 years) relapse-
free survival or developed tumour relapse within
9–76 months (~1-6 years) following surgical resection.
Our results showed that the expression of the genes
CD96, CD1d, CRTAM, LFA-1 and DNAM1, involved
in the interaction of NK cells with target cells such
as tumour cells or DCs, increased in patients with
favourable prognosis. NK cells and DCs can exchange
bidirectional activating signals in a positive feedback
loop. DCs can support innate immunity by promoting
the production of cytokines and cytotoxicity of NK cells
against cancer. Reciprocally, NK cells have been shown
to play immunoregulatory ‘helper’ functions, being able
to activate DCs and to enhance their ability to produce
pro-inflammatory cytokines during T cell responses [44].
The receptors CD96, CRTAM and DNAM1 promote
adhesion of NK cells to target cells expressing the Polio-
virus Receptor (PVR or CD155) [45,46]. This will in turn
stimulate cytotoxic function of the NK cells and CD8+
T-cell secretion of IFN-γ in vitro as well as NK cell–me-
diated rejection of tumours in vivo. Also LFA-1 is critical
for NK cell cytotoxicity as it mediates NK-cell binding
to intercellular adhesion molecule1 (ICAM1) on target
cells, generating activating signals that lead to
polarization of the actin cytoskeleton and cytotoxic
granules followed by perforin and granzymes exocytosis
[47]. Besides its role in the crosstalk with target cells,
DNAM1 together with the NKG2D, is considered one of
the most important activating receptors expressed on
NK cells. However, the molecules CD96, CRTAM and
LFA1 may be expressed by activated CD8+ and CD4+ T
cells as well as monocytes [19,48]. DNAM1 or NKG2D
may also be expressed by T cells. However, it should be
noticed the expression of these molecules was positively
and significantly associated (R value > 0.86) with the
transcription of activating receptors NCRs, considered
mostly restricted to NK cells [19,49,50] . In addition, the
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accurate marker used for NK cell identification, was
observed to be significantly increased in patients with
favorable outcome ( p value 0.02) and was significantly
associated with better survival of the patients (p value
0.03).
Although the number of patients screened for the breast
cancer transcriptomic study was small, survival analyses
performed on a larger number of breast cancer patients
(n = 115) derived from four publicly available breast cancer
datasets of gene expression [29-32] revealed a significantly
(p < 0.03) better survival for patients that showed higher
expression of the NCR3 (NKp30), NCR1 (NKp46), CD96,
CRTAM, DNAM1 and NKG2D. This suggests that,
together with cells of adaptive immune system, NK cells
might play an important role in the context of tumor
immune surveillance. The absence of detection of NCR1
(NKp46) by IHC didn’t allow us to validate at protein level
a differential expression of NKp46 in patients with widely
diverging outcomes. Although we consider this as a limit
of the present study, it is important to noticed that the
evaluation of NCR1 (NKp46) expression by IHC, as well as
the evaluation of the NCR2 (Nkp44) and NCR3 (NKp30),
has always been centre of debate for lack of an appropriate
detection.
Thus a molecular screening is preferred and might be
more accurate and useful in clinical practice.
Our results also showed that the expression of KIRs
transcripts including KIR2DL3, KIR3DL3 and KIR2DL2
was negatively and significantly correlated with NCRs
expression (R value < −0.7) and was not significantly dif-
ferent in patients with widely diverging outcomes. This
evidence suggests that the balance between inhibitory
and activating pathways in NK cells is finely regulated at
the transcriptional level. Thus, molecules involved in
activating signaling of NK cells, rather than in inhibitory
one, might be considered central modulators of NK cells
function in the tumor microenvironment.
Furthermore, the expression of NK activating genes
was positive and significantly correlate with the expres-
sion of molecules involved in Th1 signaling, which we
already reported to be associated with patients’ favorable
outcome [6]. This suggests that, in the tumor micro-
environment, the evaluation of collaboration between
the innate and adaptive immune systems may be more
relevant than single system/cell analysis.
A paradoxical positive association was found between
favorable outcome and expression of FOXP3, previously
reported to be associated with worse overall survival of
patients with breast cancer [51]. This observation is, how-
ever, in line with other studies on patients with colon
cancer where an association between the infiltration of
FOXP3+ T cells and favorable prognosis was evident
[52-54]. In addition, emerging evidence suggest thatFOXP3 is variably expressed in T cells during activation
[55], as well as on tumor cells [56,57]. Finally, activated
NK cells may dominate and overcome tumor-induced
immune suppression as previously reported by our group
[15].
Conclusions
Results from the present study, together with our recently
published work [6], underline the pivotal role played by
the innate and adaptive immune systems in the tumour
milieu and their coordinated action against cancer pro-
gression. Thus, the evaluation of collaboration between
the innate and adaptive immune systems may be more
relevant than single system/cell analysis. In order to evalu-
ate whether the described results are specific for breast
cancer or can be more broadly associated with different
cancer types, similar analysis are now ongoing on speci-
mens derived from patients with different tumour types.
The identification of a subtle variation between differ-
ent tumours in the regulation of molecules mostly asso-
ciated to NK cells may lead to a better understanding of
the intimate relationship between different types of
cancer and the immune system.Additional files
Additional file 1: Table S1. Clinical information of the patients and
tumour specimens used in each assay. Relapse free outcome was assayed
considering the patients’ status at the time of the last follow up (May
2012). Patient VBR7, previously reported as relapse, is confirmed as
relapse free. Despite this patient’s outcome variation, the conclusion
previously reported [6] sustained based on retrospective repeated
analysis.
Additional file 2: Figure S1. Canonical pathway based on NK cell–DCs
crosstalk at the significance level of 0.001 in the unpaired Student’s t test.
Genes highlighted in red or green are upregulated or downregulated,
respectively, in relapse-free group of patients.
Additional file 3: Figure S2. Canonical pathway based on NK signalling
at the significance level of 0.001 in the unpaired Student’s t test. Genes
highlighted in red or green are up regulated or down regulated,
respectively, in relapse-free group of patients.
Additional file 4: Figure S3. A) Expression of FOXP3 in relapse-free and
progressing patients; B) Expression of KIR2DL3, KIR3DL3 and KIR2DL2 in
relapse-free and progressing patients; C) IHC sections of formalin-fixed
paraffin-embedded tumour tissues of breast cancer patients; D) Survival
risk prediction analysis based on Age and ER, PR and HER2 status of
breast cancer patients.
Additional file 5: Table S2. Survival Analysis. Type of univariate test
used: Cox proportional hazards model, Wald Statistic. Permutation p-
values for significant genes were computed based on 10000 random
permutations. Hazard ratio is the ratio of hazards for a two-fold change in
the gene expression level. It is equal to exp (b) where b is the Cox
regression coefficient.Competing interests
None of the authors has a conflict of interest regarding this study.
Authors’ contributions
All authors read and approved the final manuscript.
Ascierto et al. Journal of Translational Medicine 2013, 11:145 Page 10 of 11
http://www.translational-medicine.com/content/11/1/145Acknowledgment
We gratefully acknowledge the support of VCU Massey Cancer Centre, the
Commonwealth Foundation for Cancer Research.Funding
Patient tissue samples and services in support of the research project were
provided by the VCU Massey Cancer Centre Tissue and Data Acquisition and
Analysis Core, supported, in part, with funding from NIH-NCI Cancer Centre
Support Grant P30 CA016059. Davide Bedognetti was supported by the
Conquer Cancer Foundation of the American Society of Clinical Oncology
(2011 YIA). MH Manjili, HD Bear, MO Idowu, CI Dumur, KK Payne, E Wang and
FM Marincola hold a patent assigned to Virginia Commonwealth University
(VCU) titled “Gene Signatures with rejection or recurrence of Cancer” PCT/
US2012/030312.
Author details
1Infectious Disease and Immunogenetics Section (IDIS), Department of
Transfusion Medicine, Clinical Center and FOCIS Center of Excellence,
National Institutes of Health, Bethesda, MD, USA. 2Department of Pathology,
Virginia Commonwealth University, Massey Cancer Centre, Richmond, VA,
USA. 3Biometric research Branch, Division of Cancer Treatment and
Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda,
MD, USA. 4Weill Cornell Medical College (WCMC), Doha, Qatar. 5Department
of Microbiology & Immunology, Virginia Commonwealth University, Massey
Cancer Centre, Richmond, VA, USA. 6Department of Human Genetics, Virginia
Commonwealth University, Massey Cancer Centre, Richmond, VA, USA. 7Unit
of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori
Fondazione “G. Pascale”, Naples, Italy. 8Department of Health Sciences and
Centre of Excellence for Biomedical Research University of Genoa, Genoa,
Italy. 9Department of Surgery, Virginia Commonwealth University, Massey
Cancer Centre, Richmond, VA, USA. 10IRCCS Az.Osp.Univ., San Martino-IST
Istituto Nazionale Ricerca sul Cancro, Genoa, Italy. 11Laboratory of
Lymphocyte Function, Department of Biochemistry & Cancer Biology, School
of Medicine, Meharry Medical College, Vanderbilt-Ingram Cancer Centre,
Vanderbilt University, Nashville, TN, USA. 12Chief Research Officer Sidra
Medical and Research Centre, Doha, Qatar. 13Present Address: Infectious
Disease and Immunogenetics Section (IDIS), Department of Transfusion
Medicine, National Institutes of Health, Bldg 10, Room 1N224, 9000 Rockville
Pike, Bethesda, MD 20892, USA.
Received: 1 March 2013 Accepted: 4 June 2013
Published: 12 June 2013References
1. Ascierto ML, Giorgi VD, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L,
Ayotte BD, Stroncek DF, Chouchane L, et al: An immunologic portrait of
cancer. J Transl Med 2011, 9:146.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of
immune cells within human colorectal tumors predict clinical outcome.
Science 2006, 313:1960–1964.
3. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C,
Wind P, Marliot F, Bruneval P, et al: In situ cytotoxic and memory T cells
predict outcome in patients with early-stage colorectal cancer.
J Clin Oncol 2009, 27:5944–5951.
4. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance
of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Cancer Res 2001, 61:3932–3936.
5. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H,
Camacho FM, Marincola FM, Garrido F, Cabrera T: Regression of melanoma
metastases after immunotherapy is associated with activation of antigen
presentation and interferon-mediated rejection genes. Int J Cancer 2012,
131:387–395.
6. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C,
Wang E, Ramakrishnan V, Wang XY, et al: A signature of immune function
genes associated with recurrence-free survival in breast cancer patients.
Breast Cancer Res Treat 2012, 131:871–880.
7. Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F,
Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM: CD8 T cell
help for innate antitumor immunity. J Immunol 2007, 179:6651–6662.8. Wang E, Worschech A, Marincola FM: The immunologic constant of
rejection. Trends Immunol 2008, 29:256–262.
9. Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L,
Bear HD, Manjili MH: Activated NKT cells and NK cells render T cells
resistant to myeloid-derived suppressor cells and result in an effective
adoptive cellular therapy against breast cancer in the FVBN202
transgenic mouse. J Immunol 2011, 187:708–717.
10. Moretta L: NK cell-mediated immune response against cancer.
Surg Oncol 2007, 16(Suppl 1):S3–5.
11. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L: Targeting natural killer
cells and natural killer T cells in cancer. Nat Rev Immunol 2012,
12:239–252.
12. Ames IH, Garcia AM, John PA, Litty CA, Farrell MA, Tomar RH: Decreased
natural cytotoxicity in mice with high incidence of mammary
adenocarcinoma. Clin Immunol Immunopathol 1986, 38:265–273.
13. Cook JL, Lewis AM Jr: Immunological surveillance against DNA-virus
-transformed cells: correlations between natural killer cell cytolytic
competence and tumor susceptibility of athymic rodents. J Virol 1987,
61:2155–2161.
14. Shanker A, Buferne M, Schmitt-Verhulst AM: Cooperative action of CD8 T
lymphocytes and natural killer cells controls tumour growth under
conditions of restricted T-cell receptor diversity. Immunology 2010,
129:41–54.
15. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J,
Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, et al: Human
breast cancer cells enhance self tolerance by promoting evasion from
NK cell antitumor immunity. J Clin Invest 2011, 121:3609–3622.
16. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P,
Sarabi M, Chaput N, Semeraro M, et al: Alternatively spliced NKp30
isoforms affect the prognosis of gastrointestinal stromal tumors.
Nat Med 2011, 17:700–707.
17. Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sebahoun G:
Expression of natural killer cell activating receptors in patients with
chronic lymphocytic leukaemia. Immunology 2012, 135:151–157.
18. Ascierto ML, Kmieciak M, Idowu M, Grimes M, Dumur C, Wang E,
Marincola FM, Bear HD, Manjili MH: Signatures of Immune Function Genes
Associated with Recurrence-Free Survival in Breast Cancer Patients.
J Immunother 2010, 33:881–881.
19. Marras F, Bozzano F, De Maria A: Involvement of activating NK cell
receptors and their modulation in pathogen immunity.
J Biomed Biotechnol 2011, 2011:152430.
20. Moretta A, Biassoni R, Bottino C, Moretta L: Surface receptors delivering
opposite signals regulate the function of human NK cells. Semin Immunol
2000, 12:129–138.
21. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M,
Monaco A, Liu H, et al: Systemic treatment of xenografts with vaccinia
virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.
BMC Genomics 2009, 10:301.
22. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA
amplification for gene profiling. Nat Biotechnol 2000, 18:457–459.
23. Wang E: RNA amplification for successful gene profiling analysis.
J Transl Med 2005, 3:28.
24. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
2001, 25:402–408.
25. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K,
Hu N, Su H, Taylor PR, et al: Selection and validation of endogenous
reference genes using a high throughput approach. BMC Genomics 2004,
5:55.
26. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene
expression data using BRB-ArrayTools. Cancer Inform 2007, 3:11–17.
27. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival
from gene expression data. PLoS Biol 2004, 2:E108.
28. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J: GOBO: gene expression-
based outcome for breast cancer online. PLoS One 2011, 6:e17911.
29. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P,
Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human
breast cancer predicts mutation status, transcriptional effects, and
patient survival. Proc Natl Acad Sci USA 2005, 102:13550–13555.
30. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L,
Huang F, Klaar S, et al: Gene expression profiling spares early breast
Ascierto et al. Journal of Translational Medicine 2013, 11:145 Page 11 of 11
http://www.translational-medicine.com/content/11/1/145cancer patients from adjuvant therapy: derived and validated in two
population-based cohorts. Breast Cancer Res 2005, 7:R953–964.
31. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D,
Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al: PIK3CA
mutations associated with gene signature of low mTORC1 signaling and
better outcomes in estrogen receptor-positive breast cancer.
Proc Natl Acad Sci USA 2010, 107:10208–10213.
32. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d’Assignies MS, et al: Strong time dependence of
the 76-gene prognostic signature for node-negative breast cancer
patients in the TRANSBIG multicenter independent validation series.
Clin Cancer Res 2007, 13:3207–3214.
33. Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-
Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg DM, et al: CD84 is a survival
receptor for CLL cells. Oncogene 2013, : [Epub ahead of print].
34. Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated
suppression. Immunity 2009, 30:636–645.
35. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumour immunity:
effector response to tumour and role of the microenvironment. Lancet
2008, 371:771–783.
36. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle
AM, Thomas JM, Wang E, Marincola FM, Bedognetti D: Gene expression
profiling in acute allograft rejection: challenging the immunologic
constant of rejection hypothesis. J Transl Med 2011, 9:174.
37. Shanker A, Marincola FM: Cooperativity of adaptive and innate immunity:
implications for cancer therapy. Cancer Immunol Immunother 2011,
60:1061–1074.
38. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C,
Martos JA, Moreno M: The prognostic significance of intratumoral natural
killer cells in patients with colorectal carcinoma. Cancer 1997,
79:2320–2328.
39. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K,
Hokita S, Aikou T: Prognostic value of intratumoral natural killer cells in
gastric carcinoma. Cancer 2000, 88:577–583.
40. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M,
Callol L: Prognostic significance of tumor infiltrating natural killer cells
subset CD57 in patients with squamous cell lung cancer. Lung Cancer
2002, 35:23–28.
41. Donskov F, von der Maase H: Impact of immune parameters on long-term
survival in metastatic renal cell carcinoma. J Clin Oncol 2006,
24:1997–2005.
42. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the
potential link between conventional cancer therapy and immunity.
Exp Biol Med (Maywood) 2011, 236:567–579.
43. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G,
Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D: Human Breast Tumor
Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and
DNAM-Mediated NK Cell Recognition. Cancer Res 2011, 71:6621–6632.
44. Malhotra A, Shanker A: NK cells: immune cross-talk and therapeutic
implications. Immunotherapy 2011, 3:1143–1166.
45. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M: Cutting edge: CD96
(tactile) promotes NK cell-target cell adhesion by interacting with the
poliovirus receptor (CD155). J Immunol 2004, 172:3994–3998.
46. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M,
Smyth MJ: DNAM-1/CD155 interactions promote cytokine and NK cell-
mediated suppression of poorly immunogenic melanoma metastases.
J Immunol 2010, 184:902–911.
47. Mace EM, Zhang J, Siminovitch KA, Takei F: Elucidation of the integrin LFA-
1-mediated signaling pathway of actin polarization in natural killer cells.
Blood 2010, 116:1272–1279.
48. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews
DM, Smyth MJ, Colonna M: DNAM-1 promotes activation of cytotoxic
lymphocytes by nonprofessional antigen-presenting cells and tumors.
J Exp Med 2008, 205:2965–2973.
49. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A:
Surface NK receptors and their ligands on tumor cells. Semin Immunol
2006, 18:151–158.
50. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R,
Moretta L: Activating receptors and coreceptors involved in human
natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197–223.51. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S,
Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast
cancer. J Clin Oncol 2009, 27:1746–1752.
52. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi
C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, et al: Regulatory (FoxP3+)
T-cell tumor infiltration is a favorable prognostic factor in advanced
colon cancer patients undergoing chemo or chemoimmunotherapy.
J Immunother 2010, 33:435–441.
53. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G,
Berger A, Bruneval P, Fridman WH, Pages F, Galon J: Clinical impact of
different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg,
th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263–1271.
54. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM,
Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al: gp100 peptide
vaccine and interleukin-2 in patients with advanced melanoma.
N Engl J Med 2011, 364:2119–2127.
55. Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM:
CD8 Foxp3 tumor infiltrating lymphocytes accumulate in the context of
an effective anti-tumor response. Int J Cancer 2011, 129:636–647.
56. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T,
Barda AK, Gourgoulianis KI, Germenis AE: Foxp3 expression in human
cancer cells. J Transl Med 2008, 6:19.
57. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P,
Zuo T, et al: Somatic single hits inactivate the X-linked tumor suppressor
FOXP3 in the prostate. Cancer Cell 2009, 16:336–346.
doi:10.1186/1479-5876-11-145
Cite this article as: Ascierto et al.: Molecular signatures mostly
associated with NK cells are predictive of relapse free survival in breast
cancer patients. Journal of Translational Medicine 2013 11:145.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
